BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/8/2017 3:24:00 PM | Browse: 938 | Download: 1505
 |
Received |
|
2016-08-27 18:22 |
|
Peer-Review Started |
|
2016-08-29 19:52 |
|
To Make the First Decision |
|
2016-11-11 09:29 |
|
Return for Revision |
|
2016-11-14 16:51 |
|
Revised |
|
2016-12-06 13:47 |
|
Second Decision |
|
2016-12-14 18:34 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2016-12-28 15:16 |
|
Articles in Press |
|
2016-12-28 15:16 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-01-17 16:54 |
|
Publish the Manuscript Online |
|
2017-02-08 15:32 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tia Harmon, Adriana Harbuzariu, Viola Lanier, Crystal C Lipsey, Ward Kirlin, Lily Yang and Ruben R Gonzalez-Perez |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Cancer Institute at the National Institutes of Health |
1R41 CA183399-01A1 (to Ruben R Gonzalez-Perez) |
| National Cancer Institute at the National Institutes of Health |
5U54 CA118638 |
| National Institute of General Medical Sciences, Research Initiative for Scientific Enhancement Program |
RISE 5R25 GM058268 (to Tia Harmon) |
| Congressionally Directed Medical Research Programs-Department of Defense |
W81XWH-13-1-0382 (to Ruben R Gonzalez-Perez) |
| National Cancer Institute at the National Institutes of Health |
S21 MD000101 |
| National Cancer Institute at the National Institutes of Health |
5G12 MD0076021 |
| National Cancer Institute at the National Institutes of Health |
G12 RR026250-03 |
| National Cancer Institute at the National Institutes of Health |
NIH RR03034 |
| National Cancer Institute at the National Institutes of Health |
1C06 RR18386 (to Morehouse School of Medicine) |
|
| Corresponding Author |
Ruben R Gonzalez-Perez, PhD, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, 720 Westview Drive, Hugh Gloster Suite 329, Atlanta, GA 30310,
United States. rgonzalez@msm.edu
|
| Key Words |
Triple negative breast cancer; Obesity; Leptin; Leptin peptide receptor antagonist 2; Iron oxide nanoparticles; Chemotherapy adjuvant |
| Core Tip |
Breast cancer is the second leading cause of cancer deaths in women. Triple negative breast cancer is an aggressive subtype that lacks targeted therapy. Obesity is a risk factor for breast cancer and is associated with high leptin levels. Leptin induces the expression of cell cycle associated proteins advancing cell cycle progression. Leptin also increases breast cancer stem cell growth, which promotes chemotherapeutic resistance. We have developed a leptin antagonist linked to iron oxide nanoparticles (IONP-LPrA2) which significantly inhibits leptin-induced cell proliferation and survival of breast cancer cells treated with chemotherapeutics. IONP-LPrA2 can increase chemotherapeutic efficacy in breast cancer.
|
| Publish Date |
2017-02-08 15:32 |
| Citation |
Harmon T, Harbuzariu A, Lanier V, Lipsey CC, Kirlin W, Yang L, Gonzalez-Perez RR. Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer. World J Clin Oncol 2017; 8(1): 54-66 |
| URL |
http://www.wjgnet.com/2218-4333/full/v8/i1/54.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v8.i1.54 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
